DEERFIELD, Ill. — Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, has been rolled out to U.S. pharmacies by Takeda Pharmaceuticals U.S.A. and Lundbeck.
The companies recently announced that the trade name for their vortioxetine product in this country would be changed to Trintellix to avoid name confusion. The formulation, indication and dosages of Trintellix remain the same as that of Brintellix, which was originally approved by the Food and Drug Administration in September 2013. Working in coordination with the FDA, Takeda and Lundbeck determined that a name change would be the best way to minimize future product name confusion by patients and providers.
The newly named Trintellix will have new National Drug Code (NDC) numbers associated with the product.
